Table 2 Baseline characteristics.

Age

Median (range)

75 (70–85)

75 (70–88)

Sex

Men

43 (61)

38 (54)

Women

28 (39)

33 (46)

PS

0

32 (45)

34 (48)

1

32 (45)

32 (45)

≥2

7 (10)

5 (7.0)

Civil status

Single

26 (37)

22 (31)

Living together

45 (63)

49 (69)

BMI

Median (range)

25 (16.8–37.2)

23.3 (16.5–33.6)

Comorbidity

0–4

11 (15)

20 (28)

CIRS-G score

5–7

31 (44)

26 (37)

≥8

29 (41)

25 (35)

G8 score

Median (range)

12 (7–14)

12 (6–14)

Number of medications

0

2 (3)

6 (8.4)

1–3

33 (47)

24 (34)

4–5

19 (28)

22 (31)

6+

17 (24)

19 (27)

Treatment setting

Adjuvant

40 (56)

37 (52)

Palliative

22 (31)

22 (31)

Downstaging

7 (10)

8 (11)

Adjuvant after metastatic surgery

2 (3)

4 (5.6)

Start dose

Full

27 (38)

30 (42)

Primary dose reduction

44 (62)

41 (58)

Tumour location

Right colon

32 (45)

31 (44)

Left colon

25 (35)

29 (41)

Rectum

14 (20)

11 (16)

CT regimen length adjuvant setting

3 months

0 (0)

3 (8)

6 months

4 (100)

34 (92)

CT regimen (all patients)

Capecitabine/5-FU

21 (29.6)

26 (37)

Capeox/Folfox

35 (49.3)

23 (32)

Capiri/Folfiri

15 (21.1)

22 (31)

CT regimen

Capecitabine/5-FU

15 (37.5)

19 (51)

Adjuvant setting

Capeox/Folfox

25 (62.5)

18 (49)

CT regimen

Capecitabine/5-FU

6 (27.3)

5 (23)

Palliative setting

Capeox/Folfox

4 (18.2)

2 (9.1)

Capiri/Folfiri

12 (54.5)

15 (68)

MSI

MSI stable

56 (79)

57 (80)

MSI unstable

9 (13)

11 (16)

Not known

6 (8)

3 (4.2)

KRAS status

Mutation

39 (55)

26 (37)

No mutation

28 (40)

44 (62)

Not known

4 (6)

1 (1)

NRAS status

Mutation

3 (4)

4 (5.6)

No mutation

58 (82)

52 (73)

Not known

10 (14)

15 (21)

BRAF status

Mutation

16 (23)

12 (17)

No mutation

45 (63)

44 (62)

Not known

10 (14)

15 (21)